Skip NavigationSkip to Content
Return Return to Search Results

FXR Acetylation Is Normally Dynamically Regulated by p300 and SIRT1 but Constitutively Elevated in Metabolic Disease States

  1. Author:
    Kemper, J. K.
    Xiao, Z.
    Ponugoti, B.
    Miao, J.
    Fang, S.
    Kanamaluru, D.
    Tsang, S.
    Wu, S. Y.
    Chiang, C. M.
    Veenstra, T. D.

  2. Author Address

    Kemper, Jongsook Kim, Ponugoti, Bhaskar, Miao, Ji, Fang, Sungsoon, Kanamaluru, Deepthi, Tsang, Stephanie] Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA. [Xiao, Zhen, Veenstra, Timothy D.] NCI, Lab Prote & Analyt Technol, Adv Technol Program, SAIC Frederick Inc, Frederick, MD 21701 USA. [Wu, Shwu-Yuan, Chiang, Cheng-Ming] Univ Texas SW Med Ctr Dallas, Dept Biochem, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA. [Wu, Shwu-Yuan, Chiang, Cheng-Ming] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA.
    1. Year: 2009
  2. Journal: Cell Metabolism
    1. 10
    2. 5
    3. Pages: 392-404
  4. Type of Article: Article
  1. Abstract:

    The nuclear bile acid receptor FXR is critical for regulation of lipid and glucose metabolism. Here, we report that FXR is a target of SIRT1, a deacetylase that mediates nutritional and hormonal modulation of hepatic metabolism. Lysine 217 of FXR is the major acetylation site targeted by p300 and SIRT1. Acetylation of FXR increases its stability but inhibits heterodimerization with RXR alpha, DNA binding, and transactivation activity. Downregulation of hepatic SIRT1 increased FXR acetylation with deleterious metabolic outcomes. Surprisingly, in mouse models of metabolic disease, FXR interaction with SIRT1 and p300 was dramatically altered, FXR acetylation levels were elevated, and overexpression of SIRT1 or resveratrol treatment reduced acetylated FXR levels. Our data demonstrate that FXR acetylation is normally dynamically regulated by p300 and SIRT1 but is constitutively elevated in metabolic disease states. Small molecules that inhibit FXR acetylation by targeting SIRT1 or p300 may be promising therapeutic agents for metabolic disorders.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.cmet.2009.09.009
  3. PMID: 19883617

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel